Connie F. Cunningham v. Joseph Scibana

259 F.3d 303, 2001 U.S. App. LEXIS 17125, 2001 WL 867412
CourtCourt of Appeals for the Fourth Circuit
DecidedAugust 1, 2001
Docket00-7486
StatusPublished
Cited by40 cases

This text of 259 F.3d 303 (Connie F. Cunningham v. Joseph Scibana) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fourth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Connie F. Cunningham v. Joseph Scibana, 259 F.3d 303, 2001 U.S. App. LEXIS 17125, 2001 WL 867412 (4th Cir. 2001).

Opinion

Affirmed by published opinion. Judge MICHAEL wrote the opinion, in which Judge WILLIAMS and Judge TRAXLER joined.

OPINION

MICHAEL, Circuit Judge:

Constance Cunningham was convicted of tampering with a consumer product with reckless disregard for and extreme indifference to the risk of human death or injury, in violation of 18 U.S.C. § 1365(a). Cunningham, who is still in prison, participated in a drug treatment program in an effort to qualify for the early release that Congress allows for an inmate convicted of a “nonviolent offense.” The Federal Bureau of Prisons (BOP), however, found Cunningham ineligible for early release because a BOP policy statement classified her crime as a crime of violence in all cases. Cunningham filed an application for a writ of habeas corpus, which was denied by the district court. We are persuaded by the soundness of the BOP’s judgment, reflected in its policy statement, to classify Cunningham’s crime as one of violence. We therefore affirm.

I.

Cunningham worked as a registered nurse in an Indiana hospital. Hospital staff discovered that someone was tampering with Demerol syringes by replacing the Demerol with a saline solution. Demerol is a powerful painkiller, similar to morphine; it is used for the relief of moderate to severe pain, as a preoperative medication, and as an obstetrical analgesic. See Physicians’ Desk Reference 2571 (52d ed.1998). The police interviewed Cunningham and the four other nurses who had access to the Demerol syringes. Cunningham admitted that she had once been addicted to Demerol, but she denied current use. She agreed to a urine test, and the result was positive for Demerol.

The government indicted Cunningham for tampering with a consumer product *305 “with reckless disregard for the risk that another person will be placed in danger of death or bodily injury and under circumstances manifesting extreme indifference to such risk.” 18 U.S.C. § 1365(a). The government’s theory at trial was that Cunningham, in order to satisfy her addiction, removed the Demerol from the syringes and filled them with a saline solution to conceal her wrong-doing. The jury convicted Cunningham, and on January 26, 1996, she was sentenced to eighty-four months in prison. The Court of Appeals for the Seventh Circuit affirmed her conviction, rejecting her argument that her actions had not placed anyone in danger of “bodily injury.” See United States v. Cunningham, 103 F.3d 553 (7th Cir.1996). The court began its analysis by noting that the tampering statute defines bodily injury to include “physical pain.” See id. at 555 (citing 18 U.S.C. § 1365(g)(4)(B)). The court held that the withholding of pain medication causes “physical pain” because the act of withholding “perpetuates an injury [pain] by preventing it from being alleviated by the product designed for that end.” Id.

Cunningham is serving her sentence at the Federal Prison Camp at Alderson, West Virginia. In March 1999, after Cunningham had been in prison for over three years, the BOP informed her that she was eligible for the Comprehensive Residential Drug Abuse Program. The BOP initially told Cunningham that she would qualify for a one year reduction in her sentence upon completion of the program. In June 1999, however, the BOP reversed its position, informing Cunningham that she did not qualify for early release because she had been convicted of a “Crime of Violence as contained in the Categorization of Offenses Program Statement.” Cunningham nevertheless entered the drug treatment program and successfully completed it in July 2000.

Cunningham challenged, through the appropriate administrative channels, the BOP’s determination that she was ineligible for early release. She argued that the BOP had improperly classified her crime, tampering with a consumer product in violation of 18 U.S.C. § 1365(a), as a crime of violence. Cunningham exhausted all of her administrative remedies without any success. She then filed an application for a writ of habeas corpus under 28 U.S.C. § 2241. The magistrate judge recommended that the writ be granted, but the district judge disagreed and d'enied Cunningham’s application. We now have her appeal.

II.

We start with a description of the statutory and regulatory framework for the drug treatment program in federal prisons. Congress has ordered the BOP to provide “every prisoner with a substance abuse problem ... the opportunity to participate in appropriate substance abuse treatment.” 18 U.S.C. § 3621(e)(1). As an “[ijncentive for prisoners’ successful completion of [the] treatment program,” the statute provides that “[t]he period a prisoner convicted of a nonviolent offense remains in custody after successfully completing a treatment program may be reduced by the [BOP], but such reduction may not be more than one year from the term the prisoner must otherwise serve.” § 3621(e)(2)(B). Section 3621(e) does not define a “nonviolent offense.”

To implement the statutory scheme, the BOP has promulgated a regulation and issued a program statement. See 28 C.F.R. § 550.58; Fed. Bureau of Prisons, U.S. Dep’t of Justice, Categorization of Offenses, Program Statement 5162.04 (Oct. 9,1997). The regulation repeats the statutory language, stating that only an inmate *306 convicted of a nonviolent offense who successfully completes the drug treatment program is eligible for early release. Like the statute, the regulation does not define a “nonviolent offense.” See 28 C.F.R. § 550.58. Section 6 of the program statement fills in the definitional gap by designating certain offenses as “Crimes of Violence in All Cases.” Program Statement 5162.04 § 6(a). An inmate convicted of one of these designated “crimes of violence” has not committed a “nonviolent offense” and is therefore ineligible for early release under the drug treatment program. Cunningham’s offense, tampering with a consumer product in violation of 18 U.S.C. § 1365(a), is listed in the program statement as a crime of violence in all cases. See Program Statement 5162.04 § 6(a). The BOP relied on this listing in the program statement to deny Cunningham early release under 18 U.S.C. § 3621(e)(2)(B).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Untitled Case
D. Maryland, 2026
Skanes v. Carter
D. Maryland, 2025
Paul Nicoletti v. M. Bayless
Fourth Circuit, 2025
Benson v. Carter
D. Maryland, 2024
Torok v. Carter
D. Maryland, 2024
Hallman v. United States
W.D. North Carolina, 2020
Hopper v. United States
W.D. North Carolina, 2020
GUILFORD COLLEGE v. MCALEENAN
M.D. North Carolina, 2020
Adams v. Stewart
D. Maryland, 2020
Boyd v. United States
W.D. North Carolina, 2019
Simpson v. United States
W.D. North Carolina, 2019
James v. United States
W.D. North Carolina, 2019
Pileggi v. United States
W.D. North Carolina, 2019
Guilford Coll. v. McAleenan
389 F. Supp. 3d 377 (M.D. North Carolina, 2019)
Thomas Hogge v. Eric Wilson
648 F. App'x 327 (Fourth Circuit, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
259 F.3d 303, 2001 U.S. App. LEXIS 17125, 2001 WL 867412, Counsel Stack Legal Research, https://law.counselstack.com/opinion/connie-f-cunningham-v-joseph-scibana-ca4-2001.